Photo of Dr Jesus Enrique Salcedo Sora

Dr Jesus Enrique Salcedo Sora M.D., Ph.D.

Senior Research Fellow Liverpool Shared Research Facilities

    About

    Personal Statement

    I obtained a medical degree and a master of science in Biochemistry from the National University of Colombia. Later on I was awarded a scholarship to undertake a PhD in applied molecular genomics at The University of Manchester. I then spent the next four years as a Wellcome Trust International Fellow in Tropical Medicine at the University Militar "Nueva Granada", Colombia, before joining the Molecular and Parasitology Group at the Liverpool School of Tropical Medicine. I was later appointed Lecturer in Microbiology in the School of Health Sciences of Liverpool Hope University. I have now moved to the University of Liverpool Institute for Integrative Biology.

    Together with Professor Douglas B. Kell I have applied the tremendous capabilities of flow cytometry in automated high throughput workflows to study membrane transport and cell membrane and wall biology in bacteria. These are structures at the interface in the mechanism of action of antibiotics. Our published work substantiates and expands on my previous work on persistence (different to resistance) to antibiotics. This is a stochastic driven phenomenon which, similarly to other non-deterministic processes, will benefit from applying a system biology data-driven approach to construct a framework that could facilitate our understanding of how microbial cell growth allows survival under unpredictable environments without sacrificing reproduction.

    Currently, I am the manager of the automation and synthetic biology facility GeneMill, part of the Liverpool Shared Research Facilities at the University of Liverpool: https://www.liverpool.ac.uk/health-and-life-sciences/research/liverpool-shared-research-facilities/multi-omics/genemill/. This is a synthetic biology automated laboratory that assist research and development in the University. We also engage with external collaborators from the public as well as private sector. The latter has included small and medium size enterprises together with big industry such as Unilever. GeneMill has expanded to offer the production of recombinant proteins in bacteria and yeast.